Efavirenz is mainly metabolized by cytochrome P450 2B6 (CYP2B6). This study aimed to
examine the frequencies of CYP2B6 and the association between CYP2B6 polymorphisms …

Background Human immunodeficiency virus type 1 (HIV-1) infections with a plasma
efavirenz concentration of< 1,000 ng/mL appear to have a high risk for the emergence of …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Interindividual variability in efavirenz
plasma concentrations is associated with CYP2B6 genetic polymorphisms.• Twenty‐nine …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Cytochrome P450 (CYP) 2B6
polymorphisms, particularly c. 516G→ T, are strongly associated with plasma efavirenz …

The aim of this study was to assess the influence of host genetic variations and clinical
factors in relation to efavirenz level in HIV-1 infected Thai adults. A total of 100 HIV-infected …

Objective Efavirenz, an antiretroviral medicine, is extensively metabolized by cytochrome
P450 2B6 (CYP2B6), UDP-glucuronosyltransferase 2B7 (UGT2B7), and CYP2A6. In this …

Objectives The main aim of this study was to investigate the effect of CYP2B6 gene
polymorphisms on efavirenz (EFV) plasma concentrations in Han Chinese patients with …

Objectives Efavirenz is widely used in first-line antiretroviral therapy in sub-Saharan Africa.
However, exposure to efavirenz shows marked interindividual variability that is genetically …

Aims Genetic factors, notably CYP2B6 516G→ T [rs3745274] and 983T→ C [rs28399499],
explain much of the interindividual variability in efavirenz pharmacokinetics, but data from …

Objective: UDP-glucuronosyltransferase (UGT) 2B7 was recently identified as the main
enzyme mediating efavirenz N-glucuronidation. In this study, we determined whether …